# A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19

> **NCT04770467** · PHASE2 · WITHDRAWN · sponsor: **Brii Biosciences, Inc.**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** BRII-196 and BRII-198
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04770467
- **Lead sponsor:** Brii Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02
- **Primary completion:** 2022-10
- **Final completion:** 2022-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study will no longer move forward due to recent changes in COVID-19 cases in Hong Kong.
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04770467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04770467, "A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04770467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*